Concinnity Genetics Raises £3M Seed Funding Led by Eos Advisory

Concinnity Genetics, a gene control company based in Edinburgh, has secured £3 million in an oversubscribed seed funding round. This new funding is a big step for the company as it works to make gene therapies safer and more effective.

The investment was led by Eos Advisory, with participation from Scottish Enterprise, Old College Capital (OCC)—the University of Edinburgh’s venture investment fund—and Maven Capital Partners. These investors bring strong expertise in supporting early-stage science and technology companies, further backing Concinnity’s vision.

Industry background and impact

Concinnity Genetics stands at the intersection of AI innovation and synthetic biology, addressing one of the biggest challenges in gene therapy: safety. The company’s unique RNA-based systems leverage advanced AI-driven design to enable real-time adjustments to treatments, reducing side effects and improving outcomes.

“By combining synthetic biology and AI-machine learning, the Concinnity technology has been described as the ‘holy grail for emerging gene therapies’, making such treatments both more effective and safer.”

Andrew McNeill, Managing Partner at Eos Advisory

This approach has the potential to reshape the cell and gene therapy market, creating treatments that adapt dynamically to patient needs while giving developers unprecedented control over their therapies. Concinnity’s AI platform is a key driver behind these innovations, providing the computational power and insights to design therapies that are safer and more reliable.

Use of funds

The £3m investment will allow Concinnity to spin out from the University of Edinburgh and establish its own operations in Scotland’s thriving life sciences hub. This transition marks a significant step in bringing their AI-powered technology to market.

The funding will be used to:

• Launch three new RNA-based control systems targeting critical applications in the cell and gene therapy space.
• Enhance their existing platform with data that demonstrates the commercial and clinical potential of their systems, paving the way for key industry partnerships.

“Our ambition is to be the go-to partner for gene control to make gene and cell therapies as safe as possible. This commitment from our investors, building on the ongoing support from Scottish Enterprise, speaks to the potential they see in our work, and we look forward to using the funding to further develop our technology.”

Jessica Birt, CEO and Co-founder

Company background

Concinnity Genetics is a spinout from the University of Edinburgh, originating in the lab of Professor Susan Rosser at the UKRI UK Centre for Mammalian Synthetic Biology. The company was co-founded by Jessica Birt, who serves as CEO, and Dr. Matthew Dale, both of whom bring extensive experience in AI and synthetic biology.

What sets Concinnity apart is its focus on combining AI with RNA-based control systems.

Using its advanced AI platform, the company designs therapies that can adjust dynamically after being administered. This technology not only ensures safer outcomes for patients but also gives therapy developers the confidence to push the boundaries of innovation.

With its AI-driven design tools, Concinnity is making gene therapy smarter, safer, and more adaptable, opening up new possibilities for advanced therapeutics.

Investors and historical funding overview

Concinnity’s investors include some of the most experienced players in early-stage science and technology funding:

• Eos Advisory: Backing innovative companies that address global challenges, with a focus on healthcare and sustainability.
• Scottish Enterprise: A longstanding supporter of Concinnity through its High Growth Spinout Programme, which helped the company refine its AI-powered technology.
• Old College Capital (OCC): Supporting groundbreaking ideas emerging from the University of Edinburgh.
• Maven Capital Partners: Investing in high-growth companies across the UK, with expertise in scaling innovative businesses.

These investors provide the financial and strategic backing needed to scale Concinnity’s AI-enabled RNA technologies, bridging the gap between academic research and global commercialization.